The global genomics market could reach USD 110.4 billion by 2034 in the bear case or USD 149.36 billion in the bull case, according to a new study from Contrive Datum Insights. The base case sits between the two at USD 129.88 billion by 2034, up from USD 45 billion in 2025 and USD 50.63 billion in 2026, a compound annual growth rate of 12.5% across the forecast period.
Two assumptions separate the scenarios. In the bull case, clinical reimbursement pathways for genomic testing widen faster than assumed and sequencing costs fall ahead of the historical trend, pulling forward adoption in oncology and population screening programs. In the bear case, reimbursement expansion and regulatory clearances for clinical genomic tests move slower than assumed and instrument capital costs stay elevated. Sequencing volume then takes longer to shift from research laboratories into clinical and agricultural use.
The study treats expanding clinical adoption of next-generation sequencing in oncology and rare disease diagnostics as the largest single contributor to growth, and rates its impact high. The market covers instruments, reagents, consumables and analytical services for sequencing, genotyping and functional characterization of DNA and RNA. Buyers include pharmaceutical and biotechnology developers, clinical and hospital laboratories, academic and government institutes, and agricultural and forensic laboratories.
By deliverables, Consumables & Reagents holds the largest share in 2025 at 34%, worth USD 15.3 billion, and still carries 32% in 2034. It grows at 11.74%, a little under the market's 12.5%. Computational Services is the fastest line at 16.72%, lifting its share of revenue from 5% to 7% and its value from USD 2.25 billion to USD 9.09 billion.
North America leads regionally with 42% of 2025 revenue, or USD 18.9 billion, and reaches USD 49.35 billion by 2034. Asia Pacific gains ground, moving from 24% of revenue in 2025 to 29% in 2034, with revenue climbing from USD 10.8 billion to USD 37.66 billion. Middle East and Africa stays the smallest region at 4% in both years. The United States is the largest single country market at USD 14.74 billion in 2025, or 32.76% of global revenue.
Within application and technology, Real-Time PCR leads in 2025 with 16% of revenue at USD 7.2 billion, while Bisulfite Sequencing grows fastest at 16.78%. Among proteomics tools, Mass Spectrometry leads with 24% of revenue at USD 10.8 billion and Bioinformatics grows fastest at 15.9%. By end-use, Pharmaceutical & Biotechnology Companies lead with 34% of revenue at USD 15.3 billion, and Hospitals & Clinics grow fastest at 15.32%. Oncology is the largest application area, with 38% of 2025 revenue at USD 17.1 billion.
Of everything the study models, the pace of reimbursement and regulatory clearance for clinical tests matters most. It decides how quickly sequencing volume moves into hospitals and clinics, the end-use line growing fastest, and it is the assumption that moves the market toward one end of the range or the other.
The report segments the market across five axes, with revenue and a growth rate for every line in every year from 2020 to 2034, plus bear, base and bull scenarios for the headline total. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. It is delivered as a PDF, and a free sample is available on request.